搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
clinicaltrialsarena
1 天
Teva touts safety profile of once-monthly schizophrenia therapy
The new safety data from Phase III and I trials showing an absence of postinjection syndrome, a rare and serious side effect ...
BioSpace
2 天
5 Schizophrenia Candidates Chasing BMS’ KarXT
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...
BioSpace
2 天
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
4 天
Teva Reports Positive Phase 3 Results For TEV-749 In Schizophrenia Treatment
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...
Macau Business
4 天
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial ...
The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.
Medscape
4 天
Will 'Game-Changer' Antipsychotic Live Up to the Hype?
The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...
6 天
Newron presents H1 2024 results and provides business update
Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈